Regenxbio (RGNX) Cash & Equivalents (2014 - 2025)

Regenxbio's Cash & Equivalents history runs 12 years deep, the most recent figure standing at $34.5 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 40.09% year-over-year to $34.5 million in Q4 2025; TTM through Dec 2025 was $34.5 million, a 40.09% decrease from a year earlier, with the FY2025 full-year figure at $34.5 million, down 40.09% from the prior year.
• Cash & Equivalents retreated to $34.5 million in Q4 2025 per RGNX's latest filing, from $58.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $345.2 million in Q4 2021 and bottomed at $34.5 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $88.3 million (2022), against an average of $123.2 million.
• Across the five-year window, Cash & Equivalents jumped 319.94% in 2021 and sank 71.91% in 2022, its largest moves.
• Year by year, Cash & Equivalents stood at $345.2 million in 2021, then sank by 71.91% to $97.0 million in 2022, then slumped by 64.39% to $34.5 million in 2023, then soared by 66.64% to $57.5 million in 2024, then slumped by 40.09% to $34.5 million in 2025.
• Per Business Quant, the three latest RGNX Cash & Equivalents figures stand at $34.5 million (Q4 2025), $58.8 million (Q3 2025), and $79.6 million (Q2 2025).